Ethambutol: Difference between revisions
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
MYAMBUTOL'''Ethambutol''' (commonly abbreviated '''EMB''' or simply '''E''') is a [[bacteriostatic]] [[antimycobacterial]] [[drug]] prescribed to treat [[tuberculosis]].<ref name="pmid18242089">{{cite journal |author=Yendapally R, Lee RE |title=Design, synthesis, and evaluation of novel ethambutol analogues |journal=Bioorg. Med. Chem. Lett. |volume=18 |issue=5 |pages=1607–11 |year=2008 |month=March |pmid=18242089 |pmc=2276401 |doi=10.1016/j.bmcl.2008.01.065 |url=http://linkinghub.elsevier.com/retrieve/pii/S0960-894X(08)00082-6}}</ref> It is usually given in combination with other [[Tuberculosis treatment|tuberculosis drugs]], such as [[isoniazid]], [[rifampicin]] and [[pyrazinamide]]. | |||
It is sold under the trade names '''Myambutol''' and '''Servambutol'''. | |||
==Category== | ==Category== | ||
Revision as of 13:12, 27 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
MYAMBUTOLEthambutol (commonly abbreviated EMB or simply E) is a bacteriostatic antimycobacterial drug prescribed to treat tuberculosis.[1] It is usually given in combination with other tuberculosis drugs, such as isoniazid, rifampicin and pyrazinamide.
It is sold under the trade names Myambutol and Servambutol.
Category
Antimycobacterial
US Brand Names
MYAMBUTOL
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages
Mechanism of Action
References
- ↑ Yendapally R, Lee RE (2008). "Design, synthesis, and evaluation of novel ethambutol analogues". Bioorg. Med. Chem. Lett. 18 (5): 1607–11. doi:10.1016/j.bmcl.2008.01.065. PMC 2276401. PMID 18242089. Unknown parameter
|month=ignored (help)